Berberine: Pharmacological features in health, disease and aging.

Aging Alternative therapy Antimicrobial activity Berberine DNA Gero-suppression Microbial modulation Neurodegenerative and Neuropsychological disorders Obesity metabolic effects

Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
07 Feb 2023
Historique:
received: 22 06 2022
revised: 15 12 2022
accepted: 29 12 2022
entrez: 7 2 2023
pubmed: 8 2 2023
medline: 8 2 2023
Statut: aheadofprint

Résumé

Berberine is the main active compound of different herbs and is defined as an isoquinoline quaternary botanical alkaloid found in barks and roots of numerous plants. It exhibits a wide range of pharmacological effects, such as anti-obesity and antidiabetic effects. Berberine has antibacterial activity against a variety of microbiota, including many bacterial species, protozoa, plasmodia, fungi, and trypanosomes. This review describes the role of berberine and its metabolic effects. It also discussed how it plays a role in glucose metabolism, fat metabolism, weight loss, how it modulates the gut microbiota, and what are its antimicrobial properties along with its potential side effects with maximal tolerable dosage. Representative studies were considered and analyzed from different scientific databases, including PubMed and Web of Science, for the years 1982-2022. Literature analysis shows that berberine affects many biochemical and pharmacological pathways that theoretically yield a positive effect on health and disease. Berberine exhibits neuroprotective properties in various neurodegenerative and neuropsychological ailments. Despite its low bioavailability after oral administration, a plant alkaloid is a promising tool for several disorders. A possible hypothesis would be the modulation of the gut microbiome. While the evidence concerning the aging process in humans is more limited, preliminary studies have shown positive effects in several models. Berberine could serve as a potential candidate for the treatment of several diseases. Previous literature has provided a basis for scientists to establish clinical trials in humans. However, for obesity, the evidence appears to be sufficient for hands-on use.

Sections du résumé

BACKGROUND BACKGROUND
Berberine is the main active compound of different herbs and is defined as an isoquinoline quaternary botanical alkaloid found in barks and roots of numerous plants. It exhibits a wide range of pharmacological effects, such as anti-obesity and antidiabetic effects. Berberine has antibacterial activity against a variety of microbiota, including many bacterial species, protozoa, plasmodia, fungi, and trypanosomes.
OBJECTIVE OBJECTIVE
This review describes the role of berberine and its metabolic effects. It also discussed how it plays a role in glucose metabolism, fat metabolism, weight loss, how it modulates the gut microbiota, and what are its antimicrobial properties along with its potential side effects with maximal tolerable dosage.
METHODS METHODS
Representative studies were considered and analyzed from different scientific databases, including PubMed and Web of Science, for the years 1982-2022.
RESULTS RESULTS
Literature analysis shows that berberine affects many biochemical and pharmacological pathways that theoretically yield a positive effect on health and disease. Berberine exhibits neuroprotective properties in various neurodegenerative and neuropsychological ailments. Despite its low bioavailability after oral administration, a plant alkaloid is a promising tool for several disorders. A possible hypothesis would be the modulation of the gut microbiome. While the evidence concerning the aging process in humans is more limited, preliminary studies have shown positive effects in several models.
CONCLUSION CONCLUSIONS
Berberine could serve as a potential candidate for the treatment of several diseases. Previous literature has provided a basis for scientists to establish clinical trials in humans. However, for obesity, the evidence appears to be sufficient for hands-on use.

Identifiants

pubmed: 36748808
pii: CMC-EPUB-129343
doi: 10.2174/0929867330666230207112539
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Amin Gasmi (A)

Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.

Farah Asghar (F)

Department of Microbiology and Molecular Genetics (MMG), University of the Punjab, Lahore, Pakistan.

Saba Zafar (S)

The Women University, Multan, Pakistan.

Petro Oliinyk (P)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
CONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.

Oksana Khavrona (O)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
CONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.

Roman Lysiuk (R)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
CONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.

Massimiliano Peana (M)

Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Sassari, Italy.

Salva Piscopo (S)

Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.

Halyna Antonyak (H)

Ivan Franko National University of Lviv, Lviv, Ukraine.

Joeri J Pen (JJ)

Diabetes Clinic, Department of Internal Medicine, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Department of Nutrition, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Iryna Lozynska (I)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
CONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.

Sadaf Noor (S)

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.

Larysa Lenchyk (L)

National University of Pharmacy, Kharkiv, Ukraine.
CONEM Ukraine Pharmacognosy and Natural Product Chemistry Research Group, National University of Pharmacy, Kharkiv, Ukraine.

Akram Muhammad (A)

Medicine, Government College University, Faisalabad, Pakistan.

Inna Vladimirova (I)

National University of Pharmacy, Kharkiv, Ukraine.
CONEM Ukraine Pharmacognosy and Natural Product Chemistry Research Group, National University of Pharmacy, Kharkiv, Ukraine.

Natalia Dub (N)

Andrei Krupynskyi Lviv Medical Academy, Lviv, Ukraine.

Olha Antoniv (O)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
CONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.

Oksana Tsal (O)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
CONEM Ukraine Life Science Research Group, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.

Taras Upyr (T)

National University of Pharmacy, Kharkiv, Ukraine.
CONEM Ukraine Pharmacognosy and Natural Product Chemistry Research Group, National University of Pharmacy, Kharkiv, Ukraine.

Geir Bjørklund (G)

Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway.

Classifications MeSH